Changchun High-Tech Industry Group (SHE:000661) has secured approval from China's National Medical Products Administration to proceed with the clinical trial registration for its innovative drug, GenSci142 capsules.
The drug, developed by the company's subsidiary Changchun Jinsai Pharmaceutical, is indicated for the treatment of bacterial vaginosis.
The company claims that its GenSci142 capsules can "directly destroy bacterial cell walls" and "rapidly kill the main pathogens of bacterial vaginosis."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments